Tag: cancer immunotherapy market share

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Large Is the Cancer Immunotherapy Market Expected to Be in 2029?

Over the past few years, there has been a significant increase in the size of the cancer immunotherapy market. It is projected to rise from $110.91 billion in 2024 to $124.09 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 11.9%. Factors contributing to this growth during the historic period include the escalating incidence of cancer, the preferential shift towards immunotherapy over traditional therapy, the surge in research and development activities aimed at creating targeted disease treatments, enhanced efficacy and preciseness of novel therapies, and an increasing awareness of the shortcomings associated with conventional cancer treatments.

The market size of cancer immunotherapy is predicted to undergo swift expansion in the coming years, rising to “$189.5 billion by 2029 with a compound annual growth rate (CAGR) of 11.2%.” This robust growth projected for the forecast period can be attributed to factors such as increased approval of innovative immunotherapies for cancer, heightened demand for personalized treatment, growing detection of cancer in individuals, increased investment in clinical trials for developing state-of-the-art treatments, and heightened awareness about cancer immunotherapy. Some of the main trends anticipated during the forecast period encompass the inception of adoptive cell therapies like car-t cells, investigation into the use of oncolytic viruses in cancer immunotherapy, creation of personalized cancer vaccines, application of artificial intelligence in immunotherapy research, and increased focus on real-world evidence and patient outcomes in treatment decisions.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6768&type=smp

What Are The Contributors To Demand In The Cancer Immunotherapy Market?

The cancer immunotherapy market is projected to expand due to the increasing occurrences of cancer. The global surge in cancer cases is attributed to factors such as tobacco use, alcohol consumption, obesity, lack of physical activity, and environmental elements. The rise in cancer diagnoses is projected to elevate the demand for cancer immunotherapies, as patients are progressively seeking medical treatments that offer enhanced recuperation and less discomfort. For example, the European Union Science Hub, the Joint Research Centre of the European Commission based in Belgium, reported in October 2023 that new incidents of cancer had grown by 2.3% over the prior two years, amounting to 2.74 million in 2022. In the same period, cancer deaths also rose by 2.4%. Consequently, this surge in cancer cases is anticipated to stimulate the demand for cancer immunotherapy in the future.

What Segmentation Categories Are Included In The Cancer Immunotherapy Market Analysis?

The cancer immunotherapy market covered in this report is segmented –

1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy

2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma

3) By End User: Hospitals, Cancer Research Centers, Clinics

Subsegments:

1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies

2) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

3) By Immunomodulators: Cytokines, Oncolytic Viruses, Toll-Like Receptor (TLR) Agonists

4) By Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

5) By Cell Therapy: CAR T-Cell Therapy, TCR Therapy, Natural Killer (NK) Cell Therapy

What Upcoming Trends Are Expected To Impact The Cancer Immunotherapy Market Globally?

The prominence of advanced technologies in cancer immunotherapy is a significant trend being noticed in the cancer immunotherapy market. An uptick has been noticed in the application of various innovative technologies and numerous therapies that aid the immune system to recognize and counteract tumors using a range of therapies and technologies like immuno-oncology, cryoablation, bone marrow transplant, and radiation therapy. These advanced methods may greatly impact the prognosis and treatment of cancer. For instance, in October 2022, AstraZeneca plc, a biotechnology and pharmaceutical company based in the UK, reported receiving approval for its drug, Capivasertib, paired with Faslodex. This particular drug, a cancer immunotherapy, has been created to treat breast cancer and has been revealed to be effective when used after the cancer has recurred or advanced following endocrine therapy, targeting locally advanced or metastatic breast cancer with low or negative human epidermal growth factor receptor 2 (HER2).

Who Are The Top-Ranked Companies In The Cancer Immunotherapy Market Today?

Major companies operating in the cancer immunotherapy market include Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, 3D Signatures Inc., Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, Kura Oncology Inc., MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Pulse Biosciences Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

How Is Cancer Immunotherapy Market Adoption Varying Across Different Regions And Sectors?

North America was the largest region in the cancer immunotherapy market in 2024 and is also expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=6768&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#How Large Is the Cancer Immunotherapy Market Expected to Be in 2029?#_x000D_

The size of the cancer immunotherapy market has seen swift expansion in the last few years. Predicted to escalate from a valuation of $110.91 billion in 2024 to $124.09 billion in 2025, it’s expected to experience a compound annual growth rate (CAGR) of 11.9%. Factors contributing to the growth experienced during the historical period include a rising incidence of cancer, greater inclination toward immunotherapy instead of conventional therapies, burgeoning research and development efforts targeting specific diseases, improved effectiveness and precision of recently-developed therapies, and increasing acknowledgment of the drawbacks associated with traditional cancer treatments._x000D_

_x000D_

The market size for cancer immunotherapy is predicted to experience swift expansion in the approaching years. The value is set to rise at a compound annual growth rate (CAGR) of 11.2%, reaching $189.5 billion by 2029. This anticipated upsurge during the forecast period is largely due to the rising approvals of innovative immunotherapies for cancer cure, swelling demand for tailored medicine, climbing instances of cancer diagnoses, escalating investment in clinical studies for new treatment methods, and heightened awareness about cancer immunotherapy. The projection period will witness several prominent trends, such as increasing implementation of adoptive cell therapies, notably car-t cells, leveraging oncolytic viruses in cancer immunotherapy, the advancement of bespoke cancer vaccines, the application of artificial intelligence in research on immunotherapy, and a growing focus on real-world evidence and patient results when making treatment plans._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=6768&type=smp_x000D_

_x000D_

#What Are The Contributors To Demand In The Cancer Immunotherapy Market?#_x000D_

The anticipated surge in cancer occurrences is predicted to stimulate the cancer immunotherapy market. Tobacco, alcohol, obesity, inactive lifestyle, and ecological factors are all contributing to the worldwide increase in cancer incidents. This surge is projected to augment the demand for cancer immunotherapies, as patients are showing a tendency to invest in medical procedures that offer higher recuperation and minimal discomfort. For example, information from the European Union Science Hub, a Joint Research Centre of the Belgium-based European Commission, revealed a 2.3% increase in new cancer cases over the previous two years, hitting 2.74 million in 2022. In the same period, cancer deaths also rose by 2.4%. Consequently, the upward trend in cancer occurrences is anticipated to increase the demand for cancer immunotherapy throughout the prediction period._x000D_

_x000D_

#What Segmentation Categories Are Included In The Cancer Immunotherapy Market Analysis?#_x000D_

The cancer immunotherapy market covered in this report is segmented – _x000D_

_x000D_

1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy_x000D_

2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma_x000D_

3) By End User: Hospitals, Cancer Research Centers, Clinics_x000D_

_x000D_

Subsegments:_x000D_

1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies_x000D_

2) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors_x000D_

3) By Immunomodulators: Cytokines, Oncolytic Viruses, Toll-Like Receptor (TLR) Agonists_x000D_

4) By Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines_x000D_

5) By Cell Therapy: CAR T-Cell Therapy, TCR Therapy, Natural Killer (NK) Cell Therapy_x000D_

_x000D_

#What Upcoming Trends Are Expected To Impact The Cancer Immunotherapy Market Globally?#_x000D_

The increasing use of advanced technologies in cancer immunotherapy is a key emerging trend in the cancer immunotherapy market. A raft of new technologies and therapies designed to help the immune system recognize and combat tumors has been introduced, including immuno-oncology, cryoablation, bone marrow transplant, and radiation therapy. These breakthroughs could significantly impact the treatment and potential eradication of cancer. For example, in October 2022, the UK-based pharmaceutical and biotech company, AstraZeneca Plc, announced that they had obtained approval for their Capivasertib in conjunction with Faslodex. This immunotherapeutic cancer drug is designed to treat breast cancer effectively, particularly in the event of recurrence or progression following endocrine therapy for locally advanced or metastatic breast cancer with low or negative human epidermal growth factor receptor 2 (HER2)._x000D_

_x000D_

#Who Are The Top-Ranked Companies In The Cancer Immunotherapy Market Today?#_x000D_

Major companies operating in the cancer immunotherapy market include Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, 3D Signatures Inc., Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, Kura Oncology Inc., MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Pulse Biosciences Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc. _x000D_

_x000D_

#Get The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report_x000D_

_x000D_

#How Is Cancer Immunotherapy Market Adoption Varying Across Different Regions And Sectors?#_x000D_

North America was the largest region in the cancer immunotherapy market in 2024 and is also expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=6768&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Cancer Immunotherapy Market Grown from 2024 to 2025?

The size of the cancer immunotherapy market has shown swift expansion in recent times. Expected to escalate from $110.91 billion in 2024 to $125.68 billion in 2025 with a compound annual growth rate (CAGR) of 13.3%. The factors influencing this impressive growth during the historic period include an increased incidence of cancer, a marked preference for immunotherapy over traditional treatment methods, an upsurge in R&D activities for disease-specific treatments, heightened efficacy and precision of contemporary therapies, along with a burgeoning awareness of the shortcomings associated with conventional cancer treatments.

What Growth Rate Is Anticipated for the Cancer Immunotherapy Market in the Coming Years?

The market size of cancer immunotherapy is anticipated to witness swift expansion in the upcoming years. It is projected to reach $194.64 billion by 2029, with a compound annual growth rate (CAGR) of 11.6%. Factors contributing to this growth during the forecast period include the escalating approval of innovative immunotherapies for treating cancer, increased demand for tailor-made medicine, a rise in the incidence of cancer diagnoses, substantial investment in clinical research to launch advanced treatments, and escalating awareness about cancer immunotherapy. The forecast period will also see significant trends such as the emergence of adoptive cell therapies like car-t cells, the usage of oncolytic viruses in cancer immunotherapy, the creation of individualized cancer vaccines, the application of artificial intelligence in immunotherapy research, and a heightened focus on real-world evidence and patient results in treatment decisions.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6768&type=smp

Who Are the Leading Companies in the Cancer Immunotherapy Market?

Major companies operating in the cancer immunotherapy market include Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, 3D Signatures Inc., Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, Kura Oncology Inc., MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Pulse Biosciences Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc.

What Are the Key Drivers of the Cancer Immunotherapy Market?

The surge in cancer diagnoses is projected to drive the growth of the cancer immunotherapy market. The rise in cancer rates worldwide can be attributed to factors such as tobacco use, alcohol consumption, obesity, physical inactivity, and environmental factors. This increase in cancer diagnoses is predicted to spur the demand for cancer immunotherapies, as more patients are willing to invest in medical treatments that offer better healing prospects and less pain. For instance, data from the European Union Science Hub, a branch of the Belgium-based European Commission’s Joint Research Centre, revealed that in October 2023, new cancer diagnoses grew by 2.3% over the prior two years, hitting 2.74 million in 2022. Correspondingly, deaths from cancer rose by 2.4% over the previous two years. Therefore, the growing incidence of cancer is expected to fuel the demand for cancer immunotherapy in the forecast period.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=6768&type=smp

What Are the Key Market Segments in the Cancer Immunotherapy Industry?

The cancer immunotherapy market covered in this report is segmented –

1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy

2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma

3) By End User: Hospitals, Cancer Research Centers, Clinics

Subsegments:

1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies

2) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

3) By Immunomodulators: Cytokines, Oncolytic Viruses, Toll-Like Receptor (TLR) Agonists

4) By Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

5) By Cell Therapy: CAR T-Cell Therapy, TCR Therapy, Natural Killer (NK) Cell Therapy

What Are the Latest Trends in the Cancer Immunotherapy Market?

The increasing prominence of advanced technologies in cancer immunotherapy is a critical trend in the cancer immunotherapy market. The rise of treatments that leverage the immune system to recognize and target tumors through methods such as immuno-oncology, cryoablation, bone marrow transplant, and radiation therapy represents a wave of new technologies. These methods hold great promise for transforming cancer treatment outcomes. For instance, AstraZeneca plc, a pharmaceutical and biotech firm based in the UK, secured approval for its Capivasertib, combined with Faslodex, in October 2022. This immunotherapeutic cancer drug is specifically designed for breast cancer treatment, proving effective post-recurrence or progression following endocrine therapy in locally advanced or metastatic breast cancer with low or non-existent human epidermal growth factor receptor 2 (HER2).

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

What Are the Key Regional Markets in the Cancer Immunotherapy Industry?

North America was the largest region in the cancer immunotherapy market in 2024 and is also expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6768

This Report Delivers Insight On:

1. How big is the cancer immunotherapy market, and how is it changing globally?

2. Who are the major companies in the cancer immunotherapy market, and how are they performing?

3. What are the key opportunities and risks in the cancer immunotherapy market right now?

4. Which products or customer segments are growing the most in the cancer immunotherapy market?

5. What factors are helping or slowing down the growth of the cancer immunotherapy market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the cancer immunotherapy industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What is the Anticipated CAGR of the Cancer Immunotherapy Market, and What Factors Will Drive It?

The market size for cancer immunotherapy has seen rapid expansion recently. Its growth trajectory is projected to take it from $110.91 billion in 2024 to $125.68 billion in 2025, yielding a compound annual growth rate (CAGR) of 13.3%. Factors such as a growing prevalence of cancer, higher preference for immunotherapy over traditional therapy, an increase in research and development activities for disease targeting, improved efficiency and precision of modern therapies, as well as growing acknowledgment of the limitations of conventional cancer treatments, have contributed to the growth observed during the historic period.

In the coming years, the market size for cancer immunotherapy is projected to experience significant growth, expanding to $194.64 billion in 2029 with a compound annual growth rate (CAGR) of 11.6%. The anticipated growth throughout this period can be credited to factors such as the rising approval numbers of new immunotherapies for cancer treatment, an increasing demand for individualized medicine, an escalation in the detection of cancer cases, considerable investment in clinical trials to develop breakthrough treatments, and heightened awareness of cancer immunotherapy. The forecast period may also see notable trends such as the rise of adoptive cell therapies, such as car-t cells, further investigation into oncolytic viruses in cancer immunotherapy, the formulation of personalized cancer vaccines, the employment of artificial intelligence in immunotherapy research, and an increased focus on real-world evidence and patient outcomes in making treatment decisions.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6768&type=smp

What are the Fundamental Drivers and Innovations Shaping the Cancer Immunotherapy Market?

Escalating occurrences of cancer are projected to drive the cancer immunotherapy market forward. The rise in cases of cancer worldwide can be attributed to factors such as tobacco use, alcohol consumption, obesity, sedentary lifestyles, and environmental elements. The surge in cancer diagnoses is likely to stimulate demand for cancer immunotherapy, as patients are progressively investing in medical treatments that offer higher recovery rates and minimal pain. For instance, as stated by the Belgium-based European Commission’s Joint Research Centre, the European Union Science Hub, in October 2023, new cancer cases had risen by 2.3% over the previous two years, tallying up to 2.74 million in 2022. Similarly, cancer-related deaths escalated by 2.4% over the previous two years. Consequently, the heightened incidence of cancer is predicted to spur the demand for cancer immunotherapy during the forecast period.

How Is the Cancer Immunotherapy Market Segmented?

The cancer immunotherapy market covered in this report is segmented –

1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy

2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma

3) By End User: Hospitals, Cancer Research Centers, Clinics

Subsegments:

1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies

2) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

3) By Immunomodulators: Cytokines, Oncolytic Viruses, Toll-Like Receptor (TLR) Agonists

4) By Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

5) By Cell Therapy: CAR T-Cell Therapy, TCR Therapy, Natural Killer (NK) Cell Therapy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=6768&type=smp

Which Regions Are Driving the Next Phase of the Cancer Immunotherapy Market Growth?

North America was the largest region in the cancer immunotherapy market in 2024 and is also expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Key Trends Are Shaping the Future of the Cancer Immunotherapy Market?

The rise of sophisticated technologies in cancer immunotherapy is an emerging trend in the cancer immunotherapy market. Numerous innovative technologies and therapies have been developed to aid the immune system in recognizing and combatting tumors, utilizing various forms of therapy such as immuno-oncology, cryoablation, bone marrow transplantation, and radiation. These technologies hold promise to significantly influence cancer management and recovery. For example, AstraZeneca plc, a pharmaceutical and biotech firm based in the UK, announced in October 2022 that their drug, Capivasertib in combination with Faslodex, had gained approval. This drug, a cancer immunotherapeutic agent, was engineered for the treatment of breast cancer, proving effective post-recurrence or progression subsequent to endocrine therapy in locally advanced or metastatic breast cancer that is low or negative for human epidermal growth factor receptor 2 (HER2).

View the full report here:

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

How Is the Cancer Immunotherapy Market Defined and What Are Its Core Parameters?

Cancer immunotherapy refers to a type of cancer therapy that strengthens your body’s defenses against the disease. Your body’s immune system aids in the defense against infections and other disorders. White blood cells, organs, and lymphatic system tissues make up this substance. Cancer immunotherapy comes in various forms, such as cytokines and vaccines, adoptive cell therapies, oncolytic viruses, tumor-infecting viruses, and others.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6768

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the Growth Rate of the Cancer Immunotherapy Market Shape Industry Trends by 2034?

In recent times, a swift expansion has been observed in the market size of cancer immunotherapy. Predictions suggest growth from $110.91 billion in 2024, escalating to $125.68 billion in 2025, representing a compound annual growth rate (CAGR) of 13.3%. Aspects contributing to growth during this historic period include the increasing incidence of cancer, growing preference for immunotherapy over conventional therapy, escalating research and development operations for targeted diseases, improvements in the effectiveness and precision of new therapies, and an expanding awareness of the shortcomings of traditional cancer treatments.

Expectations are set for the cancer immunotherapy market to witness a significant expansion in the coming years, with predictions indicating growth to $194.64 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 11.6%. The upswing predicted within the forecast period is associated with increasing endorsements of innovative cancer immunotherapies, surge in the demand for personalized medical treatments, growing number of individuals diagnosed with cancer, improved investment in clinical research for advanced treatment methods, and increasing public awareness of cancer immunotherapy. Anticipated trends in the forecast period are inclusive of the rise of adoptive cell therapies such as car-t cells, exploration into the use of oncolytic viruses in cancer immunotherapy, advancements in customised cancer vaccines, incorporation of artificial intelligence in researching immunotherapy, and heightened focus on real-world evidence and patient outcomes in making treatment decisions.

What Major Innovations Are Driving the Accelerated Growth of the cancer immunotherapy Market?

The anticipated surge in cancer occurrences is predicted to drive the cancer immunotherapy market. The escalating rates of cancer worldwide can be attributed to various factors such as tobacco use, alcohol consumption, obesity, inactive lifestyle, and environmental influences. This surge in cancer diagnoses is likely to stimulate the demand for cancer immunotherapy, given that patients are progressively investing in treatment procedures that offer higher survival chances and lesser discomfort. For example, the European Union Science Hub, a Belgium-based Joint Research Centre of the European Commission, reported in October 2023 that new cancer cases saw a 2.3% rise over the previous two years, amounting to 2.74 million in 2022. Cancer-related deaths also saw a hike of 2.4% during the same time frame. Consequently, this rise in cancer prevalence is projected to escalate the demand for cancer immunotherapy in the forecasted period.

Get Your Free Sample of the Global Cancer Immunotherapy Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=6768&type=smp

Who Are the Key Market Players Influencing the Growth of the Cancer Immunotherapy Industry?

Major companies operating in the cancer immunotherapy market include:

• Amgen Inc._x000D_

• AstraZeneca PLC_x000D_

• F. Hoffmann-La Roche Ltd_x000D_

• Bayer AG_x000D_

• Eli Lilly and Company_x000D_

What Key Market Trends Are Shaping the Future of the Cancer Immunotherapy Industry?

The cancer immunotherapy market is witnessing a growing trend of leveraging advanced technologies. These innovative technologies, including immuno-oncology, cryoablation, bone marrow transplant, and radiation therapy, are being used in various therapies to enable the immune system to detect and combat tumors. Such integration of technologies is revolutionizing cancer treatment and recovery. For instance, in October 2022, AstraZeneca plc, a leading pharmaceutical and biotechnology company based in the UK, received authorization for the use of Capivasertib, in conjunction with Faslodex. This cancer immunotherapeutic drug, which is utilized in the treatment of breast cancer, has proven effective when used after recurrence or progression on or after endocrine therapy. It is particularly beneficial for locally advanced or metastatic breast cancer patients with low or negative human epidermal growth factor receptor 2 (HER2).

Get Instant Access to the Global Cancer Immunotherapy Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

What Are the Main Segments of the Cancer Immunotherapy Market, and How Are They Evolving?

The cancer immunotherapy market covered in this report is segmented –

1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy

2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma

3) By End User: Hospitals, Cancer Research Centers, Clinics

Subsegments:

1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies

2) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

3) By Immunomodulators: Cytokines, Oncolytic Viruses, Toll-Like Receptor (TLR) Agonists

4) By Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

5) By Cell Therapy: CAR T-Cell Therapy, TCR Therapy, Natural Killer (NK) Cell Therapy

Which Regions Are Emerging as Leaders in the Cancer Immunotherapy Market?

North America was the largest region in the cancer immunotherapy market in 2024 and is also expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Defining Features of the Cancer Immunotherapy Market?

Cancer immunotherapy refers to a type of cancer therapy that strengthens your body’s defenses against the disease. Your body’s immune system aids in the defense against infections and other disorders. White blood cells, organs, and lymphatic system tissues make up this substance. Cancer immunotherapy comes in various forms, such as cytokines and vaccines, adoptive cell therapies, oncolytic viruses, tumor-infecting viruses, and others.

Browse Through More Similar Reports By The Business Research Company:

Lung Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Isothermal Nucleic Acid Amplification Technology (INAAT) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/isothermal-nucleic-acid-amplification-technology-global-market-report

Metabolomics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the cancer immunotherapy market grown in recent years?

The oncology immunotherapy market has seen swift expansion in the recent past. Its growth is predicted to spike from $110.91 billion in 2024 to $125.68 billion in 2025, reflecting a compound annual growth rate (CAGR) of 13.3%. Factors such as an increasing incidence of cancer, a shift towards immunotherapy from conventional treatments, burgeoning research and development pursuits for specific disease treatments, enhanced efficacy and precision of the latest therapies, and a growing understanding of the shortcomings of traditional cancer treatment methods have contributed to this growth in the past years.

How is the cancer immunotherapy market size expected to evolve during the forecast period?

It is anticipated that the cancer immunotherapy market will experience significant expansion in the coming years. The market is set to escalate to $194.64 billion by 2029, with a compound annual growth rate (CAGR) of 11.6%. The upswing during this forecast period can be related to the growing approval of innovative immunotherapies for treating cancer, an increased demand for personalized medication, the rise in cancer diagnoses, increased funding in clinical trials for pioneering treatments, and heightened awareness of cancer immunotherapy. The predicted trends for this period include the development of adoptive cell therapies such as car-t cells, the investigation of oncolytic viruses in cancer immunotherapy, the creation of personalized cancer vaccines, the application of artificial intelligence in immunotherapy studies, and a heightened focus on real-world evidence and patient outcomes in treatment choices.

Get your cancer immunotherapy market report here!

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Which key drivers are propelling the cancer immunotherapy market’s growth?

It is anticipated that the cancer immunotherapy market will experience significant expansion in the coming years. The market is set to escalate to $194.64 billion by 2029, with a compound annual growth rate (CAGR) of 11.6%. The upswing during this forecast period can be related to the growing approval of innovative immunotherapies for treating cancer, an increased demand for personalized medication, the rise in cancer diagnoses, increased funding in clinical trials for pioneering treatments, and heightened awareness of cancer immunotherapy. The predicted trends for this period include the development of adoptive cell therapies such as car-t cells, the investigation of oncolytic viruses in cancer immunotherapy, the creation of personalized cancer vaccines, the application of artificial intelligence in immunotherapy studies, and a heightened focus on real-world evidence and patient outcomes in treatment choices.

What are the market segments in the cancer immunotherapy industry?

The cancer immunotherapy market covered in this report is segmented –

1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy

2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma

3) By End User: Hospitals, Cancer Research Centers, Clinics

Subsegments:

1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies

2) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

3) By Immunomodulators: Cytokines, Oncolytic Viruses, Toll-Like Receptor (TLR) Agonists

4) By Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

5) By Cell Therapy: CAR T-Cell Therapy, TCR Therapy, Natural Killer (NK) Cell Therapy

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6768&type=smp

Which leading companies are shaping the growth of the cancer immunotherapy market?

Major companies operating in the cancer immunotherapy market include Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, 3D Signatures Inc., Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, Kura Oncology Inc., MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Pulse Biosciences Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc.

What key trends are currently impacting the cancer immunotherapy market’s development?

In the cancer immunotherapy market, a notable trend is the growing adoption of advanced technologies used for cancer immunotherapy. New technologies and diverse therapies aimed at enabling the immune system to detect and combat tumors are appearing at an increasing rate. These include immuno-oncology, cryoablation, bone marrow transplants, and radiation therapy. These technological advances have the potential to bring about marked improvements in cancer treatment outcomes. For example, AstraZeneca plc, a UK-based pharmaceutical and biotechnology firm, reported in October 2022 that it had received approval for Capivasertib in combination with Faslodex, an immunotherapeutic cancer drug developed for treating breast cancer. This treatment has shown its efficacy in tackling recurrence or progression post endocrine therapy in locally advanced or metastatic breast cancer with low or negative human epidermal growth factor receptor 2 (HER2).

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6768

Which geographic areas are influencing the growth of the cancer immunotherapy market?

North America was the largest region in the cancer immunotherapy market in 2024 and is also expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Lung Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Isothermal Nucleic Acid Amplification Technology (INAAT) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/isothermal-nucleic-acid-amplification-technology-global-market-report

Metabolomics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the Growth Rate of the Cancer Immunotherapy Market Shape Industry Trends by 2034?

In recent times, a swift expansion has been observed in the market size of cancer immunotherapy. Predictions suggest growth from $110.91 billion in 2024, escalating to $125.68 billion in 2025, representing a compound annual growth rate (CAGR) of 13.3%. Aspects contributing to growth during this historic period include the increasing incidence of cancer, growing preference for immunotherapy over conventional therapy, escalating research and development operations for targeted diseases, improvements in the effectiveness and precision of new therapies, and an expanding awareness of the shortcomings of traditional cancer treatments.

Expectations are set for the cancer immunotherapy market to witness a significant expansion in the coming years, with predictions indicating growth to $194.64 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 11.6%. The upswing predicted within the forecast period is associated with increasing endorsements of innovative cancer immunotherapies, surge in the demand for personalized medical treatments, growing number of individuals diagnosed with cancer, improved investment in clinical research for advanced treatment methods, and increasing public awareness of cancer immunotherapy. Anticipated trends in the forecast period are inclusive of the rise of adoptive cell therapies such as car-t cells, exploration into the use of oncolytic viruses in cancer immunotherapy, advancements in customised cancer vaccines, incorporation of artificial intelligence in researching immunotherapy, and heightened focus on real-world evidence and patient outcomes in making treatment decisions.

What Major Innovations Are Driving the Accelerated Growth of the cancer immunotherapy Market?

The anticipated surge in cancer occurrences is predicted to drive the cancer immunotherapy market. The escalating rates of cancer worldwide can be attributed to various factors such as tobacco use, alcohol consumption, obesity, inactive lifestyle, and environmental influences. This surge in cancer diagnoses is likely to stimulate the demand for cancer immunotherapy, given that patients are progressively investing in treatment procedures that offer higher survival chances and lesser discomfort. For example, the European Union Science Hub, a Belgium-based Joint Research Centre of the European Commission, reported in October 2023 that new cancer cases saw a 2.3% rise over the previous two years, amounting to 2.74 million in 2022. Cancer-related deaths also saw a hike of 2.4% during the same time frame. Consequently, this rise in cancer prevalence is projected to escalate the demand for cancer immunotherapy in the forecasted period.

Get Your Free Sample of the Global Cancer Immunotherapy Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=6768&type=smp

Who Are the Key Market Players Influencing the Growth of the Cancer Immunotherapy Industry?

Major companies operating in the cancer immunotherapy market include:

• Amgen Inc._x000D_

• AstraZeneca PLC_x000D_

• F. Hoffmann-La Roche Ltd_x000D_

• Bayer AG_x000D_

• Eli Lilly and Company_x000D_

What Key Market Trends Are Shaping the Future of the Cancer Immunotherapy Industry?

The cancer immunotherapy market is witnessing a growing trend of leveraging advanced technologies. These innovative technologies, including immuno-oncology, cryoablation, bone marrow transplant, and radiation therapy, are being used in various therapies to enable the immune system to detect and combat tumors. Such integration of technologies is revolutionizing cancer treatment and recovery. For instance, in October 2022, AstraZeneca plc, a leading pharmaceutical and biotechnology company based in the UK, received authorization for the use of Capivasertib, in conjunction with Faslodex. This cancer immunotherapeutic drug, which is utilized in the treatment of breast cancer, has proven effective when used after recurrence or progression on or after endocrine therapy. It is particularly beneficial for locally advanced or metastatic breast cancer patients with low or negative human epidermal growth factor receptor 2 (HER2).

Get Instant Access to the Global Cancer Immunotherapy Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

What Are the Main Segments of the Cancer Immunotherapy Market, and How Are They Evolving?

The cancer immunotherapy market covered in this report is segmented –

1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy

2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma

3) By End User: Hospitals, Cancer Research Centers, Clinics

Subsegments:

1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies

2) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

3) By Immunomodulators: Cytokines, Oncolytic Viruses, Toll-Like Receptor (TLR) Agonists

4) By Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

5) By Cell Therapy: CAR T-Cell Therapy, TCR Therapy, Natural Killer (NK) Cell Therapy

Which Regions Are Emerging as Leaders in the Cancer Immunotherapy Market?

North America was the largest region in the cancer immunotherapy market in 2024 and is also expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Defining Features of the Cancer Immunotherapy Market?

Cancer immunotherapy refers to a type of cancer therapy that strengthens your body’s defenses against the disease. Your body’s immune system aids in the defense against infections and other disorders. White blood cells, organs, and lymphatic system tissues make up this substance. Cancer immunotherapy comes in various forms, such as cytokines and vaccines, adoptive cell therapies, oncolytic viruses, tumor-infecting viruses, and others.

Browse Through More Similar Reports By The Business Research Company:

Lung Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Isothermal Nucleic Acid Amplification Technology (INAAT) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/isothermal-nucleic-acid-amplification-technology-global-market-report

Metabolomics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: